Investors Sell Shares of Amgen (AMGN) on Strength (AMGN)
Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $68.80 million flowed into the stock on the tick-up and $156.39 million flowed out of the stock on the tick-down, for a money net flow of $87.59 million out of the stock. Of all equities tracked, Amgen had the 13th highest net out-flow for the day. Amgen traded up $0.41 for the day and closed at $187.76
A number of research firms recently weighed in on AMGN. BMO Capital Markets began coverage on shares of Amgen in a report on Thursday. They issued an “outperform” rating for the company. Mizuho reissued a “buy” rating and issued a $211.00 target price on shares of Amgen in a report on Tuesday, February 26th. Cowen reissued a “buy” rating and issued a $234.00 target price on shares of Amgen in a report on Tuesday, February 26th. BidaskClub lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Finally, Royal Bank of Canada reissued a “neutral” rating on shares of Amgen in a report on Friday, February 1st. Twelve equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $208.78.
The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79. The firm has a market cap of $117.12 billion, a price-to-earnings ratio of 13.04, a price-to-earnings-growth ratio of 2.25 and a beta of 1.21.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 3.09%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total transaction of $377,760.00. Following the completion of the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at $2,830,933.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. City Holding Co. boosted its stake in shares of Amgen by 0.3% during the fourth quarter. City Holding Co. now owns 18,015 shares of the medical research company’s stock valued at $3,506,000 after purchasing an additional 50 shares during the period. Miracle Mile Advisors LLC boosted its stake in shares of Amgen by 2.6% during the fourth quarter. Miracle Mile Advisors LLC now owns 1,992 shares of the medical research company’s stock valued at $388,000 after purchasing an additional 50 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management boosted its stake in shares of Amgen by 1.8% during the fourth quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 3,321 shares of the medical research company’s stock valued at $646,000 after purchasing an additional 58 shares during the period. Hudson Capital Management LLC boosted its stake in shares of Amgen by 0.7% during the fourth quarter. Hudson Capital Management LLC now owns 8,192 shares of the medical research company’s stock valued at $1,595,000 after purchasing an additional 59 shares during the period. Finally, Deane Retirement Strategies Inc. boosted its stake in shares of Amgen by 0.6% during the fourth quarter. Deane Retirement Strategies Inc. now owns 9,838 shares of the medical research company’s stock valued at $1,915,000 after purchasing an additional 60 shares during the period. 78.13% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/03/14/investors-sell-shares-of-amgen-amgn-on-strength-amgn.html.
About Amgen (NASDAQ:AMGN)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: How to calculate the intrinsic value of a stock
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.